Shares of Natco Pharma BSE 5.27 % surged higher in trade today after the US Supreme Court rejected rival TevaPharmaceutical's request for stay onCopaxone drug.
Natco BSE 5.27 % Pharma is in the process of developing generic version of Copaxone and can launch it in May 2014 subject to the USFDA approval.
Copaxone accounts for about 20 percent of sales and 50 per cent of Teva's profit. The company generated nearly $4 billion in sales from the drug.
In July, the US Court of Appeals for the Federal Circuit issued a decision in a patent fight that pits Teva against two teams developing cheaper generic forms of Copaxone: one with Novartis BSE 0.77 % AG and Momenta Pharmaceuticals Inc; and another between Mylan Inc and Natco Pharma Ltd.
Natco BSE 5.27 % Pharma is in the process of developing generic version of Copaxone and can launch it in May 2014 subject to the USFDA approval.
Copaxone accounts for about 20 percent of sales and 50 per cent of Teva's profit. The company generated nearly $4 billion in sales from the drug.
In July, the US Court of Appeals for the Federal Circuit issued a decision in a patent fight that pits Teva against two teams developing cheaper generic forms of Copaxone: one with Novartis BSE 0.77 % AG and Momenta Pharmaceuticals Inc; and another between Mylan Inc and Natco Pharma Ltd.
No comments:
Post a Comment